Chromosome Alterations Contribute to Drug Resistance in ER+ Breast Cancer
Professor Susan Clark and colleagues at the Garvan Institute of Medical Research showed that the 3D structure of DNA is 'rewired' in hormone resistant ER+ breast cancers, altering normal gene activation and repression in the cells.
Genetic Counseling 2.0
As genetic testing ramps up in the clinic and via consumer-oriented providers, companies leverage technology to scale genetic counseling services.
Illumina Debuts Two New Sequencers, Inks Dx Deal with Roche
The NextSeq 2000 and NextSeq 1000 are both designed to meet growing demand for clinical genomic data at reduced cost, while the collaboration with Roche is focused on advancing clinical diagnostics leveraging Illumina’s pan-cancer assay TruSight Oncology 500.
Researchers Discover New Gene Interaction Responsible for Cancer Metastasis
Investigators discovered that MYC and TWIST1, two transcription factors, together elicit a cytokinome whose signaling enabled crosstalk between cancer cells and host macrophages—driving tumor progression.
Johns Hopkins Researchers Refine TMB Calculations of Immunotherapy Response
The team developed a computational approach to estimate corrected TMB values for each tumor by simulating 20,000 tumors with various levels of TMB and sequencing coverage using information from the Cancer Genome Atlas to generate a correction factor for each simulated tumor based on its purity.
Chromosome Alterations Contribute to Drug Resistance in ER+ Breast Cancer
Professor Susan Clark and colleagues at the Garvan Institute of Medical Research showed that the 3D structure of DNA is 'rewired' in hormone resistant ER+ breast cancers, altering normal gene activation and repression in the cells.
Large Scale Genomic Study Uncovers New Disease Targets
Children’s Hospital of Philadelphia researchers compared the sequence data of more than 100,000 people of European ancestry and found copy number variant (CNV) associations in four major disease categories: autoimmune, cardio-metabolic, oncologic, and neurological/psychiatric diseases.
Probiotic Drink Spiked with Genetic Elements Helps Thwart Antimicrobial Resistance
The drink targets small DNA elements called plasmids that carry antibiotic resistance genes. By preventing these plasmids from replicating, the antibiotic resistance genes are displaced, effectively re-sensitizing the bacteria to antibiotics.
Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer
Biocept's Target Selector test enables physicians to identify the potential presence of NTRK fusions used to inform on treatment options.
Amgen Taps Guardant, Qiagen for AMG 510 NSCLC Companion Dx Partnerships
The deals with each partner will initially focus on the KRAS G12C mutation as found in non-small cell lung cancer (NSCLC), which accounts for approximately 13% of all NSCLC cases.
Element Biosciences Raises $80M to Accelerate Development of a New DNA Sequencing Platform
Led by ex-Illumina executives, Element’s founders believe its sequencing technology can reduce costs and inject more competition into a market dominated by their former employer.
8 Companion Diagnostic Developers Making a Mark
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark (since acquired by Agilent Technologies) received authorization to market HercepTest. The immunohistochemistry (IHC) assay was designed to detect human epidermal growth factor receptor 2 (HER2)...
